⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31694531 | 1.00 | — | — | |
| SCHEMBL30174229 | 0.85 | AGBL2 (0.38) | — | |
| SCHEMBL28966265 | 0.85 | AGBL2 (0.38) | — | |
| SCHEMBL32671163 | 0.83 | ALOX15 (0.30) | — | |
| SCHEMBL32671162 | 0.83 | ALOX15 (0.30) | — | |
| SCHEMBL14738354 | 0.74 | — | — | |
| SCHEMBL17584302 | 0.74 | — | — | |
| SCHEMBL1671404 | 0.72 | CYP2D6 (0.32) | — | |
| SCHEMBL29782963 | 0.72 | CYP2D6 (0.32) | — | |
| SCHEMBL3063881 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250129044-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2025-04-24 | — | — | US | disclosed |
| EP-4405344-A2 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | Xenon Pharmaceuticals Inc. (CA) | 2024-07-31 | — | — | EP | disclosed |
| CN-118251389-A | Pyridyl derivatives as sodium channel activators | 泽农医药公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20230122909-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE | REPARE THERAPEUTICS INC. (CA) | 2023-04-20 | — | — | US | disclosed |
| US-9738656-B2 | Pyranodipyridine compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-08-22 | — | — | US | disclosed |
| US-20170137436-A1 | Pyranodipyridine Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-05-18 | — | — | US | disclosed |
| EP-2800742-B1 | 4,4-DISUBSTITUTED-1,4-DIHYDROPYRIMIDINES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-06 | — | — | EP | disclosed |
| US-9233933-B2 | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2016-01-12 | — | — | US | disclosed |
| CN-104302626-A | 4, 4-disubstituted-1, 4-dihydropyrimidines and their use as medicaments for the treatment of hepatitis b | JANSSEN R & D IRELAND | 2015-01-21 | — | — | CN | disclosed |
| US-20150005295-A1 | 4,4-DISUBSTITUTED-1,4-DIHYDROPYRIMIDINES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2015-01-01 | — | — | US | disclosed |
| EP-2800742-A1 | 4,4-DISUBSTITUTED-1,4-DIHYDROPYRIMIDINES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen R&D Ireland (IE) | 2014-11-12 | — | — | EP | disclosed |
| WO-2013102655-A1 | 4,4-DISUBSTITUTED-1,4-DIHYDROPYRIMIDINES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN R&D IRELAND (IE) | 2013-07-11 | — | — | WO | disclosed |
| US-6969716-B2 | 5-phenyl[1,2,4]triazines as ligands for GABA-A α2/α3 receptors for treating anxiety or depression | MERCK SHARP & DOHME LTD. | 2005-11-29 | — | — | US | disclosed |
| US-20040192692-A1 | 5-Phenyl[1,2,4]triazines as ligands for GABA-A alpha2/alpha3 receptors for treating anxiety or depression | MERCK SHARP & DOHME, LTD. (GB) | 2004-09-30 | — | — | US | disclosed |